According to data from IFI Claims Patent Services, tobacco-related products, especially electronic cigarettes and heated non-combustible products, are one of the top 10 fastest growing technologies in terms of US patent grants in 2022.
Philip Morris International (PMI) is replacing its combustible cigarette business with less harmful alternatives, specifically in the "electronic cigarette/tobacco business." PMI is currently the leading company in this field, having submitted 1,364 patent applications in 2022.
Samsung, a South Korean electronics giant, has overtaken longtime leader IBM to claim the top spot in patent ownership. Following Samsung and IBM, the top eight patent holders in order are Taiwan Semiconductor Manufacturing Company, Huawei, Canon, LG Electronics, Qualcomm, Intel, Apple, and Toyota Motor Corporation.
The fastest growing technologies listed are electric digital data processing with a compound annual growth rate of 33.9%, specialized features related to Earth drilling such as artificial intelligence and simulation models with a 32.5% compound annual growth rate, computing based on biological models with a compound annual growth rate of 32.1%, and electric smoking devices with a 31.3% compound annual growth rate.
The compound annual growth rate for cigars and cigarettes is 28.3%.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
